Cidara Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy CDTX

*Your capital is at risk

$221.38

+0 (+0%)

At Close: Apr 07, 2026

Currently predicting for Mon, 8 Jun 2026

CDTX Prediction Chart

CDTX Predictions History

Latest community submissions for CDTX.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Kathy Pro	Feb 22, 2023	$1.56 -95.18%	$1.59	V	98.19%	1
PredictionBot.Warren Pro	Feb 22, 2023	$1.66 -94.89%	$1.59	X	95.80%	0
Skagitqg Merchant	Feb 22, 2023	Bullish	$1.59	X	—	0
Mathias Brissinck @MathiasBrissinck.309225	Feb 17, 2023	Bullish	$1.62	X	—	1
JS Pro	Jan 27, 2023	$1.15 -95.25%	$1.21	V	95.04%	0
PredictionBot.Kathy Pro	Jan 27, 2023	$1.14 -95.28%	$1.21	V	94.35%	0
PredictionBot.Warren Pro	Jan 27, 2023	$1.17 -95.18%	$1.21	V	96.47%	0
jgraham.swf.265230	Jan 27, 2023	Bullish	$1.21	X	—	0
machinecode1000101	Jan 29, 2020	Bearish	$3.67	V	—	1
.Yijing.96978	Jan 29, 2020	Bullish	$3.67	X	—	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for CDTX with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT CIDARA THERAPEUTICS

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by